Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients

Ozen M., Gunduz M., Ates O., Babacan T., Sever A. R., AKIN S., ...More

JOURNAL OF BUON, vol.21, no.4, pp.799-808, 2016 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 4
  • Publication Date: 2016
  • Journal Name: JOURNAL OF BUON
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.799-808
  • Keywords: adjuvant, breast cancer, trastuzumab, treatment duration, ADJUVANT TRASTUZUMAB, TARGETED THERAPY, HORMONE-RECEPTOR, TRIAL, CHEMOTHERAPY, DOXORUBICIN, PACLITAXEL, STRATEGIES, MANAGEMENT, HERCEPTIN
  • Ankara University Affiliated: Yes

Abstract

Purpose: Optimal duration of adjuvant trastuzumab therapy in early-stage HER2-positive, lymph node-negative breast cancer is unknown. To establish this, we compared 1-year and 9-week trastuzumab regimens in HER2-positive, lymph node-negative early-stage breast cancer patients.